Soubani A O, Uberti J P
Division of Pulmonary, Critical Care and Sleep Medicine, Harper University Hospital, 3990 John R-3 Hudson, Detroit, MI 48201, USA.
Eur Respir J. 2007 May;29(5):1007-19. doi: 10.1183/09031936.00052806.
The aim of the present article is to review the available clinical data on bronchiolitis obliterans following haematopoietic stem cell transplantation (HSCT). The data sources used were the Medline database and references from the identified articles related to bronchiolitis obliterans, noninfectious pulmonary complications and HSCT. HSCT is an important treatment for a variety of malignant and nonmalignant conditions. However, the procedure is limited by significant complications that may involve every organ of the body. Pulmonary complications are seen in 40-60% of HSCT recipients. The recent advances in prophylaxis and treatment of infectious complications have increased the significance of late noninfectious pulmonary conditions. Currently, bronchiolitis obliterans is one of the most challenging pulmonary complications facing clinicians who are taking care of haematopoietic stem cell transplantation recipients. This article reviews the clinical and pathological features of this condition, sheds some light on potential mechanisms of pathogenesis, and discusses the available management options.
本文旨在综述造血干细胞移植（HSCT）后闭塞性细支气管炎的现有临床数据。所使用的数据源为Medline数据库以及与闭塞性细支气管炎、非感染性肺部并发症和HSCT相关的已识别文章的参考文献。HSCT是治疗多种恶性和非恶性疾病的重要方法。然而，该手术受到可能累及身体各个器官的严重并发症的限制。40%-60%的HSCT受者会出现肺部并发症。感染性并发症预防和治疗方面的最新进展增加了晚期非感染性肺部疾病的重要性。目前，闭塞性细支气管炎是照顾造血干细胞移植受者的临床医生面临的最具挑战性的肺部并发症之一。本文综述了该疾病的临床和病理特征，阐明了潜在的发病机制，并讨论了现有的管理方案。
